logo-loader
viewSativa Group PLC

Sativa Group PLC - Food Standards Agency Regulations

RNS Number : 1509R
Sativa Group PLC
26 June 2020
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION (INCLUDING THE UNITED STATES) WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES

OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. FOR IMMEDIATE RELEASE

Sativa Group Plc
("Sativa" or the "Company" or the "Group")

Food Standards Agency (FSA) Regulations

26th June 2020

Sativa Group Plc [AQSE: SATI], the UK's leading quoted CBD wellness and medicinal cannabis Group, is working on its Novel Food application in partnership with Stillcanna Inc, and is committed to meeting the requirements of the Food Standards Agency ("FSA") concerning the safe use of CBD products and the timetable for Novel Food authorisation.

CBD extract and isolate products were confirmed as novel food products in January 2019. Under the novel food regulations, foods or food ingredients which do not have a history of consumption before May 1997 should be evaluated and authorised before they can be placed on the market.

The FSA is giving the CBD industry a deadline of the 31st March 2021 to submit valid novel food authorisation applications. After 31st March next year, only products which have submitted a valid application will be allowed to remain on the market. The authorisation process ensures novel foods meet legal standards, including on safety and content.

With the novel food's authorisation, it will mean that there is a two-step process in applications. Step one, the manufacturers of the CBD ingredient, (extract or isolate) of which genotoxicity and toxicology testing are part of that process, and step two, the manufacturer of the end consumer product who will need to conduct stability testing and apply for novel foods authorisation.

Once a CBD product is authorised that authorisation applies to that product only. This means using the same detailed production methods, for the exact same uses as described within the authorisation and using the same safety evidence base. Where a business buys CBD product from others, they must ensure these products are correctly authorised, and that they only use them in ways described in the authorisation. The Sativa Group PLC will continue to support white label customers with novel food regulatory approved products. 

The proposed combination of the Sativa Group PLC and StillCanna Inc will allow the merged company to offer a consistent seed to consumer supply from one single company. They manufacture both the CBD ingredient as well as manufacturing the end consumer product delivered to shelves. On that basis, Sativa Group PLC and StillCanna will be submitting a joint application for all combined products to provide a wide range within their portfolio of brands including Goodbody Botanicals and Goodbody Wellness for novel foods approval.

Henry Lees-Buckley, Chief Executive Office of Sativa, said: "We welcome and embrace the clarity of the regulatory framework as an important step to leading the development of a safe and legal market in the UK. We are taking seriously the guidance from the FSA to reassure our customers and distribution partners that Sativa and StillCanna are at the forefront of building a sustainable CBD wellness industry. We have invested in our infrastructure to ensure that we are fully compliant with industry regulation for each step of the manufacturing process of our CBD products. By owing each step of that process we can ensure that compliance is maintained throughout"

Sativa Group PLC is committed to manufacturing and selling the highest quality CBD wellness products in the market.  The Group have already begun the process of gaining the approvals. Sativa have hired consultancy support with GRS (Global Regulatory Services) and are in the process of delivering the required product testing. Additionally, to ensure compliance with the necessary regulations the group is working with regulators via trade bodies such as the Association for the Cannabinoid Industry (ACI).

The Directors of the Company accept responsibility for the contents of this announcement.

 

Henry Lees-Buckley 

Chief Executive Officer

Sativa Group Plc

+44 (0) 20 7971 1255

[email protected]

www.sativagroup.co.uk

 

Joseph Colliver

Chief Financial Officer

Sativa Group Plc

+44 (0) 20 7971 1255

[email protected]

www.sativagroup.co.uk

 

AQSE Growth Market Corporate Adviser

Corporate Finance 

Guy Miller/Allie Feuerlein

Peterhouse Capital Limited

+44 (0) 20 7220 9795

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NEXFAMBTMTBTTAM

Quick facts: Sativa Group PLC

Price: 2.35

Market: AQSE
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Sativa Group PLC signs LOI with Stillcanna to become part of the company

  Sativa Group PLC (AQSE: SATI) CEO Henry Lees-Buckley joined Steve Darling from Proactive to discuss the company signing a letter of intent with Stillcanna for the companies to come together as one. Lees-Buckley discusses the reason behind this move and what it does for them in...

on 11/6/20